Crossmark

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

Crossref DOI link: https://doi.org/10.1186/s40425-019-0788-5

Published Online: 2019-11-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Loupakis, Fotios https://orcid.org/0000-0001-9651-0395
Maddalena, Giulia

Depetris, Ilaria

Murgioni, Sabina

Bergamo, Francesca

Dei Tos, Angelo Paolo

Rugge, Massimo

Munari, Giada

Nguyen, Andrew

Szeto, Christopher

Zagonel, Vittorina

Lonardi, Sara

Fassan, Matteo
License Information

Text and Data Mining valid from 2019-11-08
More Information

Article History

Received: 4 September 2019

Accepted: 23 October 2019

First Online: 8 November 2019

Ethics approval and consent to participate

: The patient consented to all the reported procedure when indicated, according to local regulations and Ethics authority.

: The patient himself consented to reporting the present case.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below